Welcome to our dedicated page for Icad news (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.
iCAD, Inc. provides AI-powered cancer detection and breast health software for radiology providers, centered on the ProFound AI Breast Health Suite and ProFound Cloud. Company news has covered mammography workflow integrations, distribution and reseller partnerships, research presentations in breast cancer detection, risk evaluation, breast density assessment, and breast arterial calcification assessment, along with FDA clearance for ProFound Detection and periodic operating results.
iCAD's later corporate news and filings also document its transition from a Nasdaq-listed public company to a wholly owned subsidiary of RadNet following a completed merger in July 2025.
iCAD (NASDAQ: ICAD), a leader in medical technology for cancer detection, announced its participation in the LD 500 Virtual Conference from September 1 to 4, 2020. Michael Klein, the CEO, will present on September 1 at 11:00 AM ET and engage in one-on-one meetings. The presentation will be available via a live audio webcast. For more details about the conference and scheduling individual meetings, participants can contact LD Micro representatives.
iCAD, a leader in medical technology, announced that CEO Michael Klein will present at the Guggenheim MedTech Disruptors Summit on August 11, 2020, at 3:00pm ET. The company specializes in innovative solutions for cancer detection and therapy, including the ProFound AI™, which enhances mammography efficiency and accuracy. ProFound AI™ has shown to reduce radiologist reading time by 52.7%, improve sensitivity by 8%, and decrease patient recalls by 7.2%. The Xoft System offers targeted treatment for cancer with minimal damage to healthy tissue.
iCAD, Inc. (NASDAQ: ICAD) reported Q2 2020 revenue of $5.6 million, down 24% YoY, primarily due to COVID-19. Operating expenses were reduced by 7% to $6.7 million. The net loss for the quarter narrowed to ($2.4) million or ($0.11) per diluted share, compared to ($3.5) million in Q2 2019. The company launched ProFound AI Risk in Europe and secured a 50-license agreement with SimonMed Imaging, enhancing breast cancer detection capabilities. Cash reserves increased to $24.2 million from $15.3 million at year-end 2019.
iCAD has announced the launch of ProFound AI™ Risk, a pioneering clinical decision support tool that provides a personalized two-year breast cancer risk estimation based solely on a screening mammogram. This tool has received CE Mark approval in Europe and was unveiled at the European Congress of Radiology (ECR) virtual meeting. ProFound AI Risk combines various risk factors for improved assessment, targeting an estimated 250 million eligible women worldwide. The technology aims to enhance patient care by enabling earlier cancer detection and reducing unnecessary procedures.
iCAD (NASDAQ: ICAD) and SimonMed Imaging announced the deployment of ProFound AI™ across SimonMed's network. ProFound AI enhances the workflow for radiologists analyzing digital breast tomosynthesis (DBT), the first FDA-cleared AI for this purpose. It improves sensitivity by 8% and reduces false positives by 7.2%, cutting reading time by over 52%. Given the backlog of screenings due to the pandemic, this technology aids in efficiently managing increased patient loads. Both companies aim to enhance breast cancer detection and screening accuracy during this critical period.
iCAD (NASDAQ: ICAD) has been included in the Russell 2000® and Russell 3000® Indexes effective June 29, 2020. This inclusion is expected to enhance stock liquidity and raise investor awareness, according to CEO Michael Klein. The Russell indexes are crucial for investment managers and utilize market capitalization for membership. iCAD specializes in cancer detection and therapy, with products like ProFound AI™ and the Xoft System, which deliver innovative solutions in medical technology.
iCAD (NASDAQ: ICAD) announced a free virtual roundtable event for clinicians on June 4, 2020, focused on the effects of COVID-19 on breast cancer surgery and targeted radiation therapy. Renowned experts in breast cancer treatment will participate, discussing challenges posed by the pandemic. iCAD emphasized that its Xoft System's intraoperative radiation therapy (IORT) offers a one-time treatment option, potentially reducing hospital visits and resources needed during the pandemic. The company highlights the relevance of its technology in current healthcare challenges while promoting educational initiatives for clinicians.
iCAD announced its Q1 2020 financial results will be released after market close on May 11, 2020. The company will hold a conference call at 4:30 PM ET on the same day to discuss the results. This call will be accessible through a domestic number (888-394-8218) and an international line (323-794-2588). The conference ID is 6904669, and a webcast will be available for interested parties. iCAD specializes in innovative solutions for cancer detection and therapy.